Focal Segmental Glomerulosclerosis

Travere Therapeutics announced the FDA granted accelerated approval to Filspari, also known as sparsentan, according to a company press release.

Researchers identified functionally relevant risk factors for pediatric primary focal segmental glomerulosclerosis in African American children, according to data published in the American Journal of Kidney Diseases.

ORLANDO — In this video from ASN Kidney Week, Jula Inrig, MD, chief medical officer of Travere Therapeutics Inc., discusses the use of dapagliflozin with sparsentan as treatment for IgA nephropathy and focal segmental glomerulosclerosis.

Among patients with focal segmental glomerulosclerosis, immunosuppressant therapy reduced proteinuria but showed no certain impact on kidney function.